MEDNAX Inc (MD) Receives $54.92 Consensus Price Target from Analysts
MEDNAX Inc (NYSE:MD) has been assigned a consensus recommendation of “Hold” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $54.92.
Several analysts recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of MEDNAX from $46.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, February 12th. BMO Capital Markets increased their price objective on shares of MEDNAX from $46.00 to $58.00 and gave the company a “market perform” rating in a report on Monday, February 12th. Mizuho reaffirmed a “neutral” rating and set a $53.00 price objective (up from $49.00) on shares of MEDNAX in a report on Friday, February 9th. Jefferies Group set a $50.00 price objective on shares of MEDNAX and gave the company a “hold” rating in a report on Tuesday, February 6th. Finally, Stephens set a $62.00 price objective on shares of MEDNAX and gave the company a “buy” rating in a report on Thursday, February 8th.
In related news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.40% of the company’s stock.
Shares of MEDNAX (NYSE:MD) traded up $0.59 during mid-day trading on Tuesday, hitting $54.87. 1,210,000 shares of the company traded hands, compared to its average volume of 1,049,584. The company has a market cap of $5,146.59, a P/E ratio of 15.90, a price-to-earnings-growth ratio of 1.36 and a beta of 0.26. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.60. MEDNAX has a 1-year low of $40.56 and a 1-year high of $72.08.
MEDNAX (NYSE:MD) last announced its earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.83 by $0.04. The business had revenue of $910.82 million during the quarter, compared to the consensus estimate of $884.55 million. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. MEDNAX’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.00 EPS. equities research analysts anticipate that MEDNAX will post 4.03 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “MEDNAX Inc (MD) Receives $54.92 Consensus Price Target from Analysts” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/mednax-inc-md-receives-54-92-consensus-price-target-from-analysts/1907696.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.